Long-term effects of amino-bisphosphonates on circulating γδ T cells

Calcified Tissue International

Volumn 91, Issue 6, 2012, Pages 395-399

  Rossini, Maurizio ^a   Adami, Silvano ^a   Viapiana, Ombretta ^a   Fracassi, Elena ^a   Ortolani, Riccardo ^b   Vella, Antonio ^b   Zanotti, Roberta ^a   Tripi, Gaia ^a   Idolazzi, Luca ^a   Gatti, Davide ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

T cell; Acute phase response; Bisphosphonate; T cell

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; DESENSITIZATION; DRUG EFFECT; DRUG INFUSION; FEMALE; FOLLOW UP; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SENILE OSTEOPOROSIS; SINGLE DRUG DOSE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; OSTEOPOROSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TIME FACTORS;

EID: 84871241943     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9647-9     Document Type: Article

References (25)

1. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V (1987) The acute-phase response after bisphoshonate administration. Calcif Tissue Int 41:326-333
2. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE (1995) Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethyl-amino-hydroxy-propylidene bisphosphonate. J Bone Miner Res 10:956-962
3. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133-139
4. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K (2009) Peripheral blood monocytes are responsible for gamma delta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144:245-250
5. Thompson K, Rogers MJ (2004) Statins prevent bisphosphonateinduced T-cell proliferation and activation in vitro. J Bone Miner Res 19:278-288
6. Kunzmann V, Bauer E, Wilhelm M (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737-738
7. Kunzmann V, Bauer E, Feurle J, Weibinger F, Tony HP, Wilhelm M (2000) Stimulation of cd T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384-392
8. Das H, Wang L, Kamath A, Bukowski JF (2001) Vc2Vd2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98:1616-1618
9. Thompson K, Rogers MJ (2006) Bisphosphonates and cd T-cells: new insights into old drugs. BoneKEy Osteovision 3:5-14
10. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380-4387
11. Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D (2012) Circulating cd T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res 27:227-230
12. Argentati K, Re F, Donnini A, Tucci MG, Franceschi C, Bartozzi B, Bernardini G, Provinciali M (2002) Numerical and functional alterations of circulating cd T lymphocytes in aged people and centenarians. J Leukoc Biol 72:65-71
13. Caccamo N, Dieli F, Wesch D, Jornaa H, Eberl M (2006) Sexspecific phenotypical and functional differences in peripheral human Vc9/Vd2 T cells. J Leukoc Biol 79:663-666
14. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri A, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC (2007) Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67:7450-7457
15. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patientswith lymphoidmalignancies. Blood 102:200-206
16. Srivastava T, Haney CJ, Alon US (2009) Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res 24:334-337
17. Thompson K, Keech F, McLernon DJ, Vinod K, May RJ, Simpson WG, Rogers MJ, Reid DM (2011) Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone 49:140-145
18. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A (2003) Induction of cd T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102:2310-2311
19. Lymperi S, Ersek A, Ferraro F, Dazzi F, Horwood NJ (2011) Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood 117:1540-1549
20. Kabelitz D, Wesch D, He W (2007) Perspectives of human cd T cells in tumor immunology. Cancer Res 67:5-8
21. Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577-3581
22. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582-3590
23. Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonate and reduced risk of colorectal cancer. J Clin Oncol 29:1146-1150
24. Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T, Ichikawa T (2011) Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 19:169-173
25. Sendur MA, Aksoy S, Yaman S, Ank Z, Ozdemir NY, Zengin N, Altundag K (2012) Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. Med Oncol. doi:10.1007/s12032- 012-0209-9